GSK Says No To Early Stage Deal-Making, Citing High Likelihood Of Failure
This article was originally published in PharmAsia News
GlaxoSmithKline's in-licensing efforts will focus on late-stage compounds due to the high risk of earlier stage deals, CEO J.P. Garnier said Feb. 8
You may also be interested in...
India is currently a viable option for simple chemistry outsourcing and offshoring; however, additional skill development is needed before medicinal chemistry and biology operations can be conducted there, speakers said at the Financial Times Global Pharmaceuticals & Biotechnology conference in London Sept. 18
GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses
Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said